Pasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III Trial - MacKenzie Feder, J; Bourdeau, I; Vallette, S; Beauregard, H; Ste-Marie, L G; Lacroix, A (Pituitary, 2014)